Michael Kramer

TL;DR: The therapeutic strategy could become a new standard of care after autologous stem-cell transplantation; however, prophylactic platelet transfusion should remain the standard for patients with acute myeloid leukaemia.

TL;DR: CD33 and CD123 expression on AML blasts was studied by flow cytometry in a cohort of 319 patients with detailed information on French–American–British/World Health Organization (FAB/WHO) classification, cytogenetics and molecular aberrations to stimulate the development of novel concepts to redirect immune effector cells toward CD33- andCD123-expressing blasts using bi-specific antibodies or engineered T cells expressing chimeric antigen receptors.

TL;DR: 7.5 microg/kg per day lenograstim proved to be safe and effective for mobilizing hematopoietic stem cells for allogeneic transplantation and long-term monitoring of healthy PBSC donors remains important to guarantee the safety standards of PBSC mobilization and collection.

TL;DR: The results in a large data set define and optimize cutoff values for early diagnosis of molecular relapse and may be especially important for defining triggers for early therapeutic intervention.

TL;DR: Findings underline the hypothesis that germ-line polymorphisms may play an important role in individualizing chemotherapy in AGC and deserve further prospective evaluation inAGC patients.